SpectronRx

SpectronRx is a pharmaceutical contract development and manufacturing organization (CDMO) More information can be found at SpectronRx.com.

SpectronRx is a Contract Development and Manufacturing Organization (CDMO) based in Indianapolis, Indiana, focused on diagnostic and therapeutic solutions for the pharmaceutical industry (clinical and commercial pharmaceutical supply, with special focus on radiopharmaceuticals), as well as nucleic acid testing of coronavirus.

05/25/2026

This Memorial Day, we pause to honor and remember the brave men and women who made the ultimate sacrifice in service to our country. Their courage, dedication, and selflessness will never be forgotten. We remember with gratitude and honor their legacy today and always.

05/12/2026

The next chapter of radiopharmaceutical innovation will not be defined by science alone. It will be defined by the ability to develop, manufacture, and deliver at the pace the market now demands.

That is why SpectronRx is excited to attend the SNMMI 2026 Annual Meeting.

📍 Visit us at Booth 1023.

As more therapies advance toward commercialization, companies need partners capable of supporting far more than a single step in the process. From isotope production and analytical testing to contract development and GMP manufacturing, SpectronRx brings together the infrastructure and operational coordination required to help programs move forward with confidence. Built for the realities of Radiopharma, our facilities are designed to help innovators reduce complexity, accelerate ex*****on, and prepare for long-term scale.

We look forward to connecting with partners, customers, and industry leaders shaping the future of nuclear medicine and precision medicine in Los Angeles.

05/05/2026

At SpectronRx, we believe that reliability accelerates results.

With 5 global locations, 50+ clean rooms, and over 420,000 sq. ft. of production space, SpectronRx delivers the infrastructure behind next-generation radiopharmaceuticals. From isotope supply to commercial manufacturing, reliability matters!

👉 Experience the difference: SpectronRx.com

04/29/2026

Great perspective in AJMC - The American Journal of Managed Care from Tyler Middlebrooks, MS on the growing value of Radioligand Therapy in community oncology.

As the field advances, expanding access matters just as much as innovation itself. Patients should not have to travel long distances to receive leading-edge care. Bringing advanced therapies closer to home can improve convenience, continuity and the overall treatment experience for patients and families.

At SpectronRx, we believe the future of radiopharmaceuticals depends on the infrastructure that helps make access possible, from isotope supply to reliable manufacturing and delivery in a time-sensitive, decay-driven environment.

Community oncology will play an increasingly important role in helping more patients benefit from the next generation of precision medicine.

👉 Learn more here: https://www.ajmc.com/view/the-value-of-radioligand-therapy-in-community-oncology-world-class-care-close-to-home

04/27/2026

SpectronRx is heading to SNMMI 2026 Annual Meeting, and we look forward to connecting with partners, peers, and other industry leaders shaping the future of nuclear medicine.

📍Visit us at Booth 1023.

As demand accelerates across theranostics and precision medicine, success depends on more than great science. It requires dependable infrastructure, coordinated ex*****on, and the ability to move at commercial speed. That is where SpectronRx is built differently. With isotope production, contract development, and GMP manufacturing capabilities under one roof, our platform is designed to help programs advance with greater speed, reliability, and confidence.

If you’ll be in Los Angeles, let’s talk about how the right partner can help move your program forward.

👉 Learn more by visiting our Website: https://www.spectronrx.com

04/24/2026

ICYMI: Plus Therapeutics announced the initiation of manufacturing activities and technology transfer with SpectronRx in support of late-stage clinical manufacturing for Rhenium-186 and REYOBIQ.

We’re proud to support this important program as an additional GMP manufacturing site and look forward to what’s ahead.

👉 Check out today’s Contract Pharma for more: https://www.contractpharma.com/breaking-news/plus-therapeutics-initiates-manufacturing-activities-tech-transfer-with-spectronrx/

04/23/2026

Proud to support Plus Therapeutics, Inc. as they advance late-stage clinical manufacturing for Rhenium-186 and REYOBIQ.

This milestone reflects the importance of building resilient, scalable supply chain infrastructure across radiopharmaceutical development. In a time-sensitive, decay-driven environment, reliable manufacturing capacity and trusted ex*****on matter.

With SpectronRx serving as an additional GMP manufacturing site, this collaboration underscores how strong partnerships help move promising therapies closer to patients. We appreciate the opportunity to support this important program and look forward to the road ahead.

👉 Read more here: https://ir.plustherapeutics.com/news-releases/news-release-details/plus-therapeutics-initiates-manufacturing-activities-spectronrx

04/21/2026

In a time-sensitive, decay-driven environment, access changes everything.

✔️ 21+ isotopes.
✔️ One integrated platform.
✔️ Endless possibilities.

From Ac-225 and Pb-212 to Cu-64, Ga-68, and Lu-177, SpectronRx supports the full spectrum of radiopharmaceutical development and manufacturing, helping partners move with speed, scale, and confidence.

👉 Learn more: SpectronRx.com

04/17/2026

Congratulations to the team at Telix Pharmaceuticals on dosing the first patient in the Phase III IPAX BrIGHT trial evaluating TLX101-Tx for recurrent glioblastoma.

This milestone marks an important step forward in addressing one of the most challenging cancers, where new therapeutic approaches are urgently needed. The study’s combination of targeted radiopharmaceutical therapy with established chemotherapy highlights the growing momentum behind precision medicine in oncology.

It is also encouraging to see the integration of diagnostic and therapeutic capabilities, with TLX101-Px (Pixclara) supporting both patient selection and response assessment. This kind of end-to-end approach reflects where the field is headed.

👉 Read more here: https://www.auntminnie.com/clinical-news/molecular-imaging/nuclear-medicine/news/15822312/telix-doses-first-patient-in-glioblastoma-trial

04/15/2026

Exciting news for medical professionals and the patients they serve. Stanford researchers have developed a novel PET imaging tracer designed to detect the earliest signs of multiple sclerosis before symptoms appear. In these studies, the tracer identified elevated immune activity in the spinal cord during the presymptomatic stage, offering a potential window into disease processes long before traditional imaging methods detect damage.

This kind of advancement underscores a broader shift in precision medicine: moving from reactive diagnosis to proactive detection. Because in diseases like MS, earlier insight doesn’t just improve understanding; it can transform outcomes.

At SpectronRx, we are proud to deliver the essential infrastructure that powers advancements like this. Our expertise in isotope production and GMP manufacturing ensures that next-generation imaging agents reach clinics safely and efficiently. By providing unmatched precision, reliability, and scale, we enable researchers and healthcare professionals to translate breakthroughs from bench to bedside—driving better patient outcomes and supporting innovation at every step.

👉 Read more about it here: https://med.stanford.edu/radiology/news/2026-news/novel-pet-imaging-tracer-detects-early-signs-of-multiple-scleros.html

04/13/2026

We’re excited to welcome Joanna Suan as VP of Marketing & Strategy at SpectronRx.

Joanna joins us from GE HealthCare, where she spent more than 20 years leading global marketing initiatives across molecular imaging and PET radiopharmacy. Throughout her career, she has helped shape strategy around the future of radionuclide supply while supporting customers worldwide in advancing precision imaging and theranostics.

Her experience at the intersection of commercial strategy, customer engagement, and radiopharmaceutical innovation comes at a pivotal moment for our company and the industry.

“Joanna brings a rare combination of deep industry expertise and strategic vision,” said John Zehner, CEO of SpectronRx. “As we continue to scale our integrated platform, her leadership will play a critical role in strengthening our market position and accelerating our growth.”

As demand for radiopharmaceuticals continues to accelerate, scaling the right infrastructure and aligning it with market needs has never been more important. Joanna will play a critical role in sharpening our strategic direction, deepening customer alignment, and ensuring our growth continues to match the pace of this rapidly evolving industry.

Please join us in welcoming Joanna to the team.

Address

17490 Dugdale Drive
South Bend, IN
46635

Website

http://www.spectronrx.com/

Alerts

Be the first to know and let us send you an email when SpectronRx posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to SpectronRx:

Shortcuts

Want your business to be the top-listed Business in South Bend?